Genentech, Inc.

F. Hoffmann-la Roche Ag

Stuart Ward

Monique Bodil Van Niel

Benjamin Fauber

Christopher Hurley

Olivier Rene

Andrew Peter Cridland

Jonathan Killen

Alberto Gobbi

Emanuela Gancia

Paul Winship

Simon Gaines

David Robert Vesey

Huifen Chen

James John Crawford

Matthew Volgraf

Elisia Villemure

Daniel Shore

Aijun Lu

Robin Larouche-Gauthier

Francis Beaumier

Sarah Bronner

Martin Dery

Tammy Ladduwahetty

Joseph P Lyssikatos

Janusz Jozef Kulagowski

Peter Scott Dragovich

Brian Salvatore Safina

Hazel Joan Dyke

Wendy Lee

Sharada Shenvi Labadie

Mark Edward Zak

Srinivasan Babu

Emily J Hanan

Paul Gibbons

Rohan V Mendonca

Jason R Zbieg

David Nigel Hurst

Lea Constantineau-Forget

Chantal Grand-Maitre

Baihua Hu

Jack Alexander Terrett

Bohdan Waszkowycz

Patrick Cyr

Robert Maxey

Michael Koehler

Tony Johnson

Stefan Gradl

Phillippe Bergeron

Rebecca Pulk

David Hurst

David Vesey

Andrew Cridland

Tammy Laddywahetty

Compounds of formula I: or pharmaceutical salts thereof,wherein m, n, p, q A, B, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Pyridazine derivatives as RORc modulators

The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.

Oxadiazolones as transient receptor potential channel inhibitors

The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Oxadiazole transient receptor potential channel inhibitors

Compounds of formula I: or pharmaceutical salts thereof,wherein m, n, A, R1, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Compounds of formula I: or pharmaceutical salts thereof,

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X, X, X, X, Y, Z, A, R, R, R, R, RR, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.

Aryl sultam derivatives as RORc modulators

Compounds of the formula I: or a pharmaceutical salt thereof,wherein X, Ar, R1, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Compounds of the formula I: or pharmaceutically acceptable salts thereof,wherein m, n, p, q, r, A, W, X, X, X, X, Y, Z, R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Compounds of the formula Ia or Ib: or pharmaceutically acceptable salts thereof,wherein m, n, p, q, r, A, X, X, X, X, Y, Z, R, R, R, R, R, R, R, and Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Benzyl sulfonamide derivatives as RORc modulators

Compounds of the formula Ia or Ib: or pharmaceutically acceptable salts thereof,wherein m, n, r, A, X, X, X, X, Y, Z, R, R, R, R, R, R, R, and Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Compounds of the formula I: or pharmaceutically acceptable salts thereof,wherein m, n, p, q, r, A, W, X, X, X, X, Y, Z, R, R, R, R, R, R, R, R, R, R, R, and Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Compounds of the formula I: or pharmaceutically acceptable salts thereof,wherein m, n, p, q, r, A, X, X, X, X, X, X, Y, Z, G, R, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Aryl sulfamide and sulfamate derivatives as RORc modulators

The invention provides novel compounds of formula I having the general formula: wherein R, R, R, X and Y are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.

Tricyclic heterocyclic compounds, compositions and methods of use thereof

Growing community of inventors

Harlow, United Kingdom

Stuart Ward